Andreanne M. Lacroix

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

E. Furth, E. Wherry, E. Jaffee, 2021, Clinical Cancer Research.

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

H. Maecker, J. Seigne, L. Appleman, 2021, Journal for ImmunoTherapy of Cancer.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors

V. Velcheti, M. Ernstoff, Jeffrey S. Miller, 2018, Clinical Cancer Research.

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study.

M. Sznol, M. Ernstoff, L. Fong, 2019, JAMA oncology.

PHASE I TRIAL OF ALT-803, A NOVEL RECOMBINANT INTERLEUKIN-15 COMPLEX, IN PATIENTS WITH ADVANCED SOLID TUMORS

V. Velcheti, M. Ernstoff, Jeffrey S. Miller, 2018 .

Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses

P. Danaher, C. Morrison, Song Liu, 2022, Science Translational Medicine.

A phase 1b/2a study of safety and efficacy of NT-I7 in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory (R/R) high-risk skin cancers: The phase 1b report.

J. Sosman, P. Friedlander, P. Funchain, 2022, Journal of Clinical Oncology.

Abstract #999926: Effect of Dosing and Titration of Osilodrostat on Efficacy and Safety in Patients With Cushing's Disease (CD): Results From Two Phase III Trials (LINC3 and LINC4)

M. Fleseriu, R. Auchus, P. Snyder, 2021, Endocrine Practice.